Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TN-401 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dose for Cohort 1 will be 3E13 vg/kg |
| Cohort 2 | EXPERIMENTAL | Dose for Cohort 2 will be 6E13 vg/kg |
| Name | Type | Description |
|---|---|---|
| TN-401 | GENETIC | TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene. It is a single (one-time) intravenous dose. |
Inclusion Criteria: * PKP2 mutation (pathogenic or likely pathogenic) * Arrhythmogenic Right Ventricular Cardiomyopathy as defined by the 2010 revised Task Force Criteria * Left Ventricular Ejection Fraction ≥50% * Functioning Implantable Cardiac Defibrillator with remote integration capabilities a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Lexeo Therapeutics, Inc. | LXEO | 3 | PHASE1 | LX2020 |
TN-401 is an investigational gene therapy being developed for the treatment of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), a cardiovascular condition. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
TN-401 is a gene therapy designed to address ARVC associated with PKP2 gene mutations. It is being studied in adults with PKP2 mutation-associated ARVC, with the goal of providing a therapeutic benefit by targeting the underlying genetic cause of the condition.
TN-401 is being developed by Tenaya Therapeutics, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and preliminary efficacy of TN-401 in patients with ARVC.
TN-401 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency and is still undergoing clinical trials to assess its safety and efficacy.
TN-401 is being studied in a Phase 1 open-label, dose escalation trial (NCT06228924) in the United States. The trial is recruiting 15 adults aged 18 years and older with PKP2 mutation-associated ARVC to evaluate the safety and preliminary efficacy of the treatment.